Keyphrases
2-dose
12%
Absolute Count
12%
CD4+
25%
CD4+ T
12%
CD4+ T Cells
12%
CD56
12%
CD8+ T
25%
CD8+ T Cells
12%
Cell Ratio
25%
Cellular Compartments
12%
Cellular Level
100%
CGP74588
12%
Clinical Benefit
12%
Combination Therapy
25%
Combinatorial Regimens
12%
Consecutive Days
12%
Disease Outcome
100%
First Cycle
12%
Fold Increase
12%
Gastrointestinal Stromal Tumor
12%
HLA-DR
100%
Imatinib Mesylate
100%
Immunological Markers
12%
Impregnation
12%
Interleukin-2
100%
Low-dose Cyclophosphamide
12%
Maximum Tolerated Dose
25%
Natural Killer Cells
100%
Oncoimmunology
12%
Overall Survival
37%
Phase I Clinical Trial
100%
Phase II Clinical Trial
12%
Progression-free Survival
25%
Rapid Expansion
12%
Refractory Solid Tumors
12%
Regulatory T Cells
12%
Therapeutic Role
12%
Treg
12%
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
12%
Immunology and Microbiology
CD4
37%
Cell Level
100%
Cyclophosphamide
12%
Cytotoxic T-Cell
37%
HLA-DR
100%
Interleukin 2
100%
Low Drug Dose
12%
Maximum Tolerated Dose
25%
Metabolite
12%
Natural Killer Cell
100%
Overall Survival
37%
Progression Free Survival
25%
Regulatory T Cell
25%
T-Helper Cell
12%
TNF related apoptosis inducing ligand
12%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
12%
Upregulation
12%
Veterinary Science and Veterinary Medicine
CD4
80%
Natural Killer Cell
100%
Regulatory T Cell
40%
T Cell
80%